Sign inJoin waitlistJoin the waitlist

Ajai Chari

Professor · University of California (San Francisco) School of Medicine

Credentials: · · · ·

History

University of California (San Francisco) School of Medicine
Present

University of California (San Francisco) School of Medicine
2005–2007
University of California-San Francisco
2002–2005
Internal Medicine
New York Presbyterian Hospital
1999–2002
David Geffen Sch of Med at UCLA
1995–1999

Research

Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2022 · 1,060 citations
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
The Lancet · 2016 · 711 citations
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
The Lancet Oncology · 2020 · 657 citations

Sundar Jagannath
78 papers
Hearn Cho
45 papers
Samir Parekh
45 papers
Joshua Richter
44 papers
Saad Usmani
44 papers
Shambavi Richard
31 papers
Paul Richardson
28 papers
DM
Deepu Madduri
27 papers
Cesar Valdes
25 papers
Ajay Nooka
22 papers
AJ
Andrzej Jakubowiak
21 papers
Jonathan Kaufman
21 papers

Clinical trials

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Principal investigator · Terminated · Phase 1, Phase 2
Ajai Chari
2018–2020
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Principal investigator · Terminated · Phase 2
Icahn School of Medicine at Mount Sinai
2017–2019
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Principal investigator · Completed · Phase 2
Ajai Chari
2014–2019
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Principal investigator · Completed · Phase 2
Ajai Chari
2013–2016